FDAnews Drug Daily Bulletin

VIVENTIA BIOTECH STRIKES DEAL TO BECOME A PRIVATE COMPANY

Nov. 15, 2005
A A

Viventia Biotech Inc. has approved a deal to become a private company as part of a plan to repay debt owed to its major shareholder. The Toronto-based cancer drug developer announced Monday it has approved a merger agreement with principal shareholders Leslie Dan, Andrea Dan-Hytman and their affiliates under which Viventia will be amalgamated with a private company owned by the Dan family.

National Post (http://www.canada.com/national/nationalpost/news/story.html?id=b7cf33d3-4850-4a55-8efb-aab2979303a7)